Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.

Other equities analysts have also issued research reports about the company. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 target price on the stock in a research note on Tuesday, August 22nd. William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Jefferies Group LLC reissued a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. BidaskClub lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Finally, Canaccord Genuity set a $47.00 target price on Atara Biotherapeutics and gave the company a “buy” rating in a research note on Monday, August 7th. Four equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Atara Biotherapeutics has a consensus rating of “Hold” and an average target price of $23.60.

Atara Biotherapeutics (ATRA) traded down 3.17% on Friday, reaching $15.25. The company had a trading volume of 232,891 shares. The company’s 50 day moving average price is $14.88 and its 200-day moving average price is $15.88. The company’s market capitalization is $466.02 million. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.05. On average, equities analysts predict that Atara Biotherapeutics will post ($3.89) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Atara Biotherapeutics, Inc. (ATRA) Upgraded at ValuEngine” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/01/atara-biotherapeutics-inc-atra-upgraded-at-valuengine.html.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 2,800 shares of the stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $16.94, for a total value of $47,432.00. Following the completion of the sale, the chief executive officer now directly owns 731,859 shares in the company, valued at $12,397,691.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Isaac E. Ciechanover sold 5,500 shares of the stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $16.49, for a total value of $90,695.00. Following the completion of the sale, the chief executive officer now owns 731,859 shares of the company’s stock, valued at $12,068,354.91. The disclosure for this sale can be found here. Insiders sold 46,109 shares of company stock worth $673,304 in the last three months. Insiders own 16.10% of the company’s stock.

Large investors have recently made changes to their positions in the company. Teachers Advisors LLC increased its stake in shares of Atara Biotherapeutics by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 137,416 shares of the biotechnology company’s stock valued at $1,951,000 after buying an additional 7,165 shares during the period. Wells Fargo & Company MN increased its stake in shares of Atara Biotherapeutics by 9.0% in the first quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock valued at $1,197,000 after buying an additional 4,791 shares during the period. Jennison Associates LLC acquired a new stake in shares of Atara Biotherapeutics during the first quarter valued at about $829,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Atara Biotherapeutics during the first quarter valued at about $185,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Atara Biotherapeutics by 5.3% in the first quarter. Bank of New York Mellon Corp now owns 120,097 shares of the biotechnology company’s stock valued at $2,468,000 after buying an additional 6,069 shares during the period. Institutional investors own 82.95% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.